Back to Search
Start Over
Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS
- Source :
- Neurology® Neuroimmunology & Neuroinflammation
- Publication Year :
- 2019
-
Abstract
- Ocrelizumab has been recently approved for relapsing-remitting MS, demonstrating a dramatic effect on MRI and clinical parameters in 2 pivotal phase III trials.1 However, long-term B-cell depletion might lead to an increased susceptibility to infections and/or to their increased severity (a case of fulminant hepatitis due to enterovirus infection has been recently reported by our group).2 Finally, depletion of B-cell compartment might impair acquisition of long-term humoral immunologic memory (i.e. production of antigen-specific class G immunoglobulins [IgG]) and might reduce T-lymphocyte response because of the absence of B lymphocyte–mediated activation. Indeed, humoral response to vaccination has been shown to be dampened or abolished in ocrelizumab-treated patients.3
- Subjects :
- Adult
Multiple Sclerosis
T cell
T-Lymphocytes
medicine.disease_cause
Antibodies, Monoclonal, Humanized
03 medical and health sciences
Young Adult
0302 clinical medicine
medicine
Humans
Immunologic Factors
030212 general & internal medicine
G immunoglobulins
Fulminant hepatitis
Clinical/Scientific Notes
B-Lymphocytes
business.industry
Vaccination
medicine.anatomical_structure
Neurology
Varicella Zoster Virus Infection
Immunology
Enterovirus
Ocrelizumab
Female
Neurology (clinical)
business
Immunologic memory
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 23327812
- Volume :
- 7
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Neurology(R) neuroimmunologyneuroinflammation
- Accession number :
- edsair.doi.dedup.....d6a9bfc1fc874044c3d5554386b4b799